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Plasmacytoid dendritic cells (pDCs) are primary pro-
ducers of type I interferon (IFN) in response to vi-
ruses. The IFN-producing capacity of pDCs is regu-
lated by specific inhibitory receptors, yet none of
the known receptors are conserved in evolution.
We report that within the human immune system, re-
ceptor protein tyrosine phosphatase sigma (PTPRS)
is expressed specifically on pDCs. Surface PTPRS
was rapidly downregulated after pDC activation,
and only PTPRS pDCs produced IFN-a. Antibody-
mediated PTPRS crosslinking inhibited pDC activa-
tion, whereas PTPRS knockdown enhanced IFN
response in a pDC cell line. Similarly, murine Ptprs
and the homologous receptor phosphatase Ptprf
were specifically co-expressed in murine pDCs.
Haplodeficiency or DC-specific deletion of Ptprs on
Ptprf-deficient background were associated with
enhanced IFN response of pDCs, leukocyte infiltra-
tion in the intestine and mild colitis. Thus, PTPRS
represents an evolutionarily conserved pDC-specific
inhibitory receptor, and is required to prevent spon-
taneous IFN production and immune-mediated in-
testinal inflammation.
INTRODUCTION
Plasmacytoid dendritic cells (pDCs) represent a distinct innate
immune cell type whose function, phenotype, and core gene
expression program are conserved across mammalian species
(Colonna et al., 2004; Liu, 2005). Despite their lymphoid
morphology, pDCs are closely related to classical DCs (cDCs)
based on their common progenitors, expression profile, andsentinel function in immunity (Merad et al., 2013; Mildner and
Jung, 2014). pDCs express endosomal Toll-like receptors
TLR7 and TLR9 that recognize their respective nucleic acid li-
gands single-stranded RNA and unmethylated CpG-containing
DNA (CpG). pDCs respond to these stimuli with rapid and abun-
dant secretion of type I interferon (interferon a or b, IFN), produc-
ing up to 1,000-fold more IFN than other cell types. This unique
IFN-producing capacity of pDCs is important for the control
of viral infections, e.g., by facilitating virus-specific T cell re-
sponses (Cervantes-Barragan et al., 2012; Swiecki et al.,
2010). Conversely, aberrant hyperactivation of pDCs has been
proposed as a common effector mechanism in several autoim-
mune diseases (Ganguly et al., 2013). Thus, IFN production by
pDCs is a powerful immune response that must be tightly regu-
lated to maintain immune homeostasis.
The pDCs possess multiple adaptations for their IFN secreting
capacity, including secretory plasma cell-likemorphology; base-
line expression of IFN gene ‘‘master regulator’’ IRF7; the recog-
nition of TLR ligands in early endosomes, facilitated by the AP-3
adaptor complex (Blasius et al., 2010; Sasai et al., 2010); and
pDC-specific membrane adaptor molecules such as Pacsin1
(Esashi et al., 2012). On the other hand, the potentially dangerous
IFN production by pDCs is restricted by a unique set of pDC-
specific receptors (Gilliet et al., 2008). Human pDCs express
several specific receptors including BDCA-2 (CD303) and ILT7
(CD85g), and their ligation by antibodies inhibits pDC function
(Cao et al., 2006; Dzionek et al., 2001). ILT7 recognizes Bst2,
an IFN-inducible protein that sends a negative feedback signal
to IFN-producing pDCs (Cao et al., 2009). In mice, SiglecH is
preferentially expressed on pDCs and inhibits IFN production
upon antibody-mediated crosslinking (Blasius et al., 2006). All
these receptors signal through ITAM-containing adaptor pro-
teins and activate an Src kinase-dependent pathway, which in-
hibits IFN production by pDCs through unknown mechanisms.
Furthermore, the role of these inhibitory receptors in pDC func-
tion and immune homeostasis in vivo is still poorly understood.
Strikingly, all known pDC-specific inhibitory receptors are uniqueImmunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc. 277
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Figure 1. PTPRS Is Expressed Specifically
in pDCs within the Human Immune System
(A) The binding of E2-2 to PTPRS locus in the
human pDC cell line CAL-1 as determined by
ChIP-seq. Shown are enrichment peaks of E2-2-
associated chromatin (top track) and total chro-
matin input (bottom track) across the indicated
loci.
(B) The expression of PTPRS after E2-2 knock-
down in the human pDC cell line Gen2.2. Cells
were treated with Dox to induce the expression of
shRNA specific for E2-2-encoding TCF4 gene or a
scrambled control (Ctrl) shRNA, and the expres-
sion of TCF4 and PTPRS was measured by qRT-
PCR on days 2 and 4. Shown is the ratio of
expression levels with or without Dox (means ± SD
of triplicate PCR reactions); representative of two
independent experiments with two TCF4-specific
shRNAs.
(C) The expression of PTPRS in primary human
peripheral blood cells as determined by qRT-PCR
(mean ± SD of triplicate reactions). CAL-1 cells
were included as a positive control.
(D and E) Cell surface expression of PTPRS on
normal human PBMC. Cells were stained with
control IgG or a polyclonal antibody to human
PTPRS, followed by secondary fluorescent anti-
body and primary antibodies to cell surface
markers. Shown is a representative staining profile
of PBMC stained for pDC marker BDCA-2 (D) and
PTPRS staining profiles in gated cell types
including BDCA2+ CD123hi pDCs, T and B lym-
phocytes, monocytes (Mono), and granulocytes
(Gran) (E). Similar results were obtained with
PBMC from multiple donors and with commercial
buffy coat samples.to their respective species: thus, BDCA-2 and ILT7 have no mu-
rine orthologs, whereas SiglecH has no human ortholog. Given
the similar function and expression profile of murine and human
pDCs, additional conserved receptors would be expected to
control pDC function in both species.
Receptor-type protein tyrosine phosphatases are widely ex-
pressed on immune cells and often restrict their activation
(Rhee and Veillette, 2012). A distinct subfamily of leukocyte
common antigen-related (LAR) receptor-type phosphatases is
composed of three homologous receptors: LAR (Ptprf), sigma
(Ptprs), and delta (Ptprd). Ptprd is brain-specific, whereas Ptprf
and Ptprs are expressedmore broadly and regulate the develop-
ment of mammary gland and brain, respectively. Ptprf and
Ptprs show partial genetic redundancy in certain murine tissues
such as the developing genitourinary tract (Uetani et al., 2009).
Expression of Ptprf was reported on immature thymocytes
(Kondo et al., 2010; Terszowski et al., 2001); however, Ptprf is
entirely dispensable for T cell development and function (Ters-
zowski et al., 2001). The expression or function of Ptprs in the im-
mune system has not been explored. Notably, polymorphisms in
the human PTPRS gene have been associated with ulcerative
colitis, and the few surviving Ptprs-deficient mice on mixed ge-
netic background develop mild colitis (Muise et al., 2007).
This was ascribed to the putative function of Ptprs in the intesti-
nal epithelial barrier (Muise et al., 2007; Murchie et al., 2014),278 Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc.although the colitis’ potential origins within the epithelial or he-
matopoietic compartment have not been investigated.
Here we report that Ptprs is expressed specifically on pDCs in
both human and murine immune systems, whereas Ptprf is simi-
larly pDC-specific in murine immune cells. The expression of
PTPRS was inversely correlated with pDC activation, and its
crosslinking inhibited cytokine production by pDCs. The reduc-
tion of Ptprs and Ptprf in mice enhanced IFN production by
pDCs and caused mild intestinal inflammation. These results
identify Ptprs as an evolutionarily conserved inhibitory receptor
on pDCs and suggest that constitutive pDC hyperactivation
might disrupt immune homeostasis in barrier tissues.
RESULTS
PTPRS Is Specifically Expressed on pDCs among Human
Immune Cells
Transcription factor E2-2 (TCF4) controls pDC development and
functionality in bothmice and humans and specifies a conserved
pDC-specific gene-expression program (Cisse et al., 2008). The
analysis of E2-2 chromatin targets in human pDCs (Ghosh et al.,
2014) revealed prominent binding of E2-2 near the promoter and
within the first intron of PTPRS (Figure 1A). As expected, the
bound regions contained multiple consensus E boxes (Fig-
ure S1A). Similar binding was observed in the CLEC4C and
A B C
D E
F
Figure 2. PTPRS Inversely Correlates with
and Inhibits the Activation of Human pDCs
(A) The dynamics of PTPRS expresion in primary
human pDCs upon activation. Total PBMCs were
cultured for 0–3 hr with CpG and stained for cell
surface markers and PTPRS. Shown are staining
profiles of gated pDCs at the indicated time points
(representative of three experiments).
(B) Intracellular distribution of PTPRS in human
pDCs upon activation. The pDCs were enriched
from PBMC, cultured with or without CpG for 4 hr,
fixed, stained for PTPRS and analyzed by immuno-
fluorescence microscopy. Representative of two
experiments.
(C) The expression of surface PTPRS in IFN-pro-
ducing human pDCs. PBMCs were cultured with or
without CpG overnight, stained for cell surface
markers, fixed, and stained for intracellular IFN-a.
Shown is the staining for PTPRS versus IFN-a in
gated pDCs (representative of four experiments).
(D) The effect of PTPRS crosslinking on IFN-a pro-
duction by primary human pDCs. PBMCs were
cultured in the presence of control IgG or anti-
PTPRS antibody for 1 hr, activated with CpG for
16 hr, and stained for cell surface markers and
intracellular IFN-a. Left panel shows representative
staining profiles of gated pDCs with the fraction of
IFN-a+ cells highlighted. Right panel shows the
fractions of IFN-a+ cells within gated pDCs from six
individual donors (mean values of two or three in-
dependent experiments per donor per condition).
(E) The effect of PTPRS crosslinking on the production of TNF-a by human pDCs. PBMCs were activated and stained as above for cell surface markers and
intracellular IFN-a and TNF-a. Shown are staining profiles of gated pDCs with the fraction of IFN-a+ TNF-a+ cells highlighted (representative of three individual
donors).
(F) The effect of PTPRS crosslinking on the activation of NF-kB in human pDCs. The pDCs were enriched from PBMC, cultured for 3 hr without (unstim.) or with
CpG in the presence of control IgG or anti-PTPRS, fixed, stained for NF-kB p65 and DNA and scored for the degree of p65 nuclear translocation. Shown are
representative immunofluorescence images of p65 staining and the percentage of pDCs with translocated p65 on the scale of 1 (full nuclear exclusion) to 4
(prominent nuclear staining), out of >200 cells in each group.LILRA4 genes encoding BDCA-2 and ILT-7, respectively, but not
in the homologous PTPRF gene (Figure 1A). Doxycycline (Dox)-
inducible knockdown of E2-2 by short interfering RNAs (shRNA)
(Sawai et al., 2013) reduced PTPRS expression in human pDC
cell lines Gen2.2 (Figure 1B) and CAL-1 (data not shown), sug-
gesting that the expression of PTPRS is E2-2-dependent.
Among major cell types in the human peripheral blood, only
pDCs expressed PTPRS transcript (Figure 1C). The expression
atlas of human immune cells showed the predominant expres-
sion of PTPRS in pDCs, similar to CLEC4C and LILRA4 (Fig-
ure S1B). Low expression of all three genes was also apparent
in the CD141+ cDCs. These data also reveal that homologous
LAR phosphatases PTPRF and PTPRD are not expressed in hu-
man immune cells. Deep sequencing of the human transcrip-
tome by the FANTOM5 consortium revealed that the expression
of PTPRS in pDCs is among the highest in the body, equaling or
exceeding the brain (Figure S1C). These studies also defined po-
tential enhancers in the first intron of PTPRS; notably, these en-
hancers appear active exclusively in pDCs and overlap with the
regions of E2-2 binding (Figure S1D).
We stained human peripheral blood mononuclear cells
(PBMC) with a polyclonal antibody against the extracellular
domain of PTPRS. Surface staining for PTPRS was restricted
to BDCA-2+ pDCs, and only pDCs, but not other cell types,showed homogeneous PTPRS expression (Figures 1D and 1E).
These data demonstrate that within the human immune system,
PTPRS is expressed specifically in the pDC lineage.
PTPRS Inversely Correlates with and Inhibits the
Activation of Human pDCs
Following the culture of PBMC with TLR9 ligand CpG, the sur-
face expression of PTPRS on pDCs was progressively reduced
within several hours (Figure 2A). Immunofluorescent staining
for PTPRS revealed diffuse intracellular signal in activated
pDCs compared to intense membrane signal in naive pDCs (Fig-
ure 2B), suggesting that PTPRS is internalized after activation. In
addition, the propensity of LAR phosphatases to undergo activa-
tion-induced shedding of their ectodomains (Aicher et al., 1997;
Ruhe et al., 2006) is also likely to contribute to the rapid loss of
PTPRS. After overnight culture, a sizable fraction of pDCs lost
surface PTPRS expression even in medium alone, whereas all
pDCs downregulated PTPRS after activation with CpG (Fig-
ure 2C). Notably, intracellular staining for IFN-a revealed that
only pDCs with the lowest PTPRS surface expression were pro-
ducing the cytokine (Figure 2C).
The inverse correlation between PTPRS expression and IFN
production suggested that active PTPRS-mediated signaling
might inhibit pDC activation. We therefore incubated PBMCImmunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc. 279
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Figure 3. PTPRS Knockdown Enhances the
Activation of a Human pDC Cell Line
(A) Western blot analysis of PTPRS and p38 (total
and phosphorylated, p-p38) in the human pDC cell
line Gen2.2 after stimulation with CpG.
(B) Inducible knockdown of PTPRS in the Gen2.2
cell line. Gen2.2 cells were transduced with retro-
viral vectors encoding two independent shRNA
for PTPRS (shRNA1 and shRNA2), and treated with
Dox to induce shRNA expression. PTPRS expres-
sion was measured 2 days later by cell surface
staining.
(C)Western blot analysis of p-p38 inGen2.2 cells that
were treated with Dox for 48 hr to induce PTPRS
knockdown and activated with CpG for 6 hr.
(D) The expression of IFNB by Gen2.2 cells after
Dox-inducible PTPRS knockdown. Cells carrying
Dox-inducible shRNAs for PTPRS were treated with
Dox for 48 hr, stimulated with type A CpG for 6 hr,
and IFNB expression was determined by qRT-PCR
(mean ± SD of triplicate reactions, representative of
three experiments).
(E) The expression of IFNB and IFN-inducible gene
CXCL10 in Gen2.2 cells with Dox-induced PTPRS
knockdown (shRNA1) at the indicated time points
after stimulation with CpG (mean ± SD of triplicate
PCR reactions; representative of three experiments).with control or anti-PTPRS antibody and analyzed CpG-induced
IFN-a production. PTPRS crosslinking reduced the fraction of
IFN-a+ activated pDCs in multiple independent donors (Fig-
ure 2D). In addition to the unique IRF7-dependent production
of IFN, TLR ligation in pDCs induces the activation of NF-kB
pathway and production of TNF-a. We found that the fraction
of TNF-a+ pDCs was reduced by PTPRS crosslinking in three in-
dependent donors (Figure 2E). Accordingly, activation-induced
nuclear translocation of NF-kB p65 in purified pDCs was also
reduced by PTPRS crosslinking (Figure 2F). Thus, forced induc-
tion of PTPRS signaling inhibits the two major outcomes of
TLR9-mediated pDC activation.
PTPRS Restricts the Activation of a Human pDC
Cell Line
To test the effect of PTPRS reduction on pDC function, we used
the human pDC cell line Gen2.2, which retains some activation
potential (Chaperot et al., 2006). Gen2.2 cells expressed PTPRS
protein, whichwas downregulated after activationwith CpG (Fig-
ure 3A). We also observed that the induction of p38 kinase phos-
phorylation, an important event in pDC activation (Takauji et al.,
2002; Zaru et al., 2015), mirrored the decrease of PTPRS (Fig-
ure 3A). Furthermore, crosslinking of PTPRS on Gen2.2 cells de-
layed the characteristic induction of both p-p38 and p-Stat1 (Di
Domizio et al., 2009) and inhibited CpG-induced nuclear translo-
cation of IRF7 (Figure S2).
To test the effect of PTPRS reduction on pDC function, we
used the Dox-inducible shRNA expression system in Gen2.2
cells. The induction of two independent PTPRS-specific shRNAs
reduced surface protein expression of PTPRS (Figure 3B).
Furthermore, Dox-induced PTPRS knockdown increased the
phosphorylation of p38 in CpG-treated Gen2.2 cells (Figure 3C).
Due to multiple rounds of selection during retrofitting and shRNA280 Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc.expression, the resulting Gen2.2 cells had only minimal IFN-a
response to CpG but manifested a robust IFN-b transcript induc-
tion. As shown in Figure 3D, CpG-induced IFNB expression
was increased after PTPRS knockdown by two shRNAs. More-
over, the induction of IFNB and of a canonical IFN-inducible
gene CXCL10 was both accelerated and prolonged (Figure 3E).
Collectively, the opposite outcomes of PTPRS crosslinking
and inducible PTPRS knockdown support the inhibitory role of
PTPRS in human pDCs.
Ptprs and Ptprf Are Coexpressed in Murine pDCs and
Inhibit Their Function
Because LAR phosphatases are highly conserved in vertebrates,
we examined whether the murine ortholog of PTPRS is similarly
expressed in the pDC lineage. By qRT-PCR, Ptprs transcript was
highly enriched in the BM and splenic pDCs, was detected at low
levels in cDCs, and was virtually absent from myeloid cells and
lymphocytes (Figure 4A). In addition, the homologous LAR phos-
phatase Ptprf was also specifically expressed in murine pDCs
(Figure 4A), in contrast to its absence from human pDCs (Fig-
ure S1A). The expression atlas of murine immune cells confirmed
the preferential expression of both Ptprs and Ptprf in pDCs (Fig-
ure S3A). The expression of Ptprs, but not of Ptprf, was reduced
after the deletion of E2-2 from murine pDCs in vivo (Ghosh et al.,
2010), confirming Ptprs as a conserved E2-2 target in both hu-
mans and mice (Figure S3B). To further analyze the expression
of murine Ptprf gene, we used aGFP reporter driven by the entire
Ptprf locus in a bacterial artificial chromosome (BAC) transgene.
As shown in Figure 4B, only pDCs expressed detectable GFP
signal, whereas all other cells were negative in PtprfGFP trans-
genic mice.
Anti-human PTPRS antibody (Figures 1 and 2) showed weak
but detectable surface staining of pDCs from wild-type mice,
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Figure 4. Ptprs and Ptprf Are Specifically Coexpressed in Murine
pDCs
(A) The expression of Ptprs and Ptprf in sorted murine immune cell types as
determined by qRT-PCR (mean ± SD of triplicate reactions). Cells included BM
granulocytes (Gran), BM and splenic pDCs, and splenic CD8+ andCD8 cDCs,
macrophages, and lymphocytes.
(B) The expression ofPtprf-GFP transgenic reporter in the indicated immune cell
populations from the spleen. Shown are representative profiles of GFP fluo-
rescence in the transgenic (Tg) and wild-type control (Ctrl) animals.
(C) Cell surface expression of LAR phosphatases inmurine pDCs. Splenocytes
from mice with the indicated Ptprs and Ptprf genotypes were stained with
control (Ctrl) or anti-PTPRS antibodies, followed by secondary fluorescent
antibody and antibodies to cell surface markers. Shown are histograms and
mean fluorescence intensities of gated pDCs and of CD8+ T cells as a negative
control cell type.
(D) The expression of LAR phosphatases in intestinal intraepithelial lympho-
cytes (IEL). IEL were isolated fromPtprf-GFP transgenic (Tg) or wild-type controlwhich was reduced in Ptprf null (Ptprs+/+ Ptprf/) and double-
haplodeficient (Ptprs+/ Ptprf+/) mice (Figure 4C). The staining
was further reduced in the Ptprf null, Ptprs-haplodeficient
(Ptprs+/Ptprf/) mice, suggesting that the antibody recognizes
both LAR phosphatases co-expressed on murine pDCs. Little or
no surface expression of Ptprs or Ptprf was observed on T cells
and other cell types in the spleen and BM (Figure 4C and data not
shown).Within leukocytes in peripheral tissues such as the intes-
tine, the expression of PtprfGFP and surface staining for Ptprs
and Ptprf were restricted to pDCs (Figure 4D). Similar to human
PTPRS, the surface expression of murine Ptprs and Ptprf was
profoundly downregulated in pDCs activated with CpG in vitro
(Figure 4E). These results suggest that Ptprs, as well as the ho-
mologous LAR phosphatase Ptprf, are specifically coexpressed
on naive quiescent pDCs and are downregulated upon
activation.
To further explore the role of LAR phosphatases in murine
pDCs, we utilized a conditionally transformed progenitor cell
line HoxB8-FL that can be differentiated into functional pDCs
(Redecke et al., 2013). We derived HoxB8-FL cells expressing
yellow fluorescent protein (YFP) reporter from the IFN-b-encod-
ing Ifnb gene and differentiating into pDCs with >90% efficiency
(Figure 5A). The differentiated HoxB8-IfnbYFP cells showed rapid
induction of YFP in response to CpG, as well as baseline expres-
sion and rapid loss of surface LAR phosphatases (Figure 5B).
Pre-incubation with plate-bound anti-PTPRS caused a signifi-
cant reduction of CpG-induced Ifnb expression (Figures 5C
and 5D). This reduction was observed even when Fc receptors
were blocked by specific antibodies or excess immunoglobulin
G (IgG) in serum, or when anti-PTPRS was bound to the plate
via the Fc portion (Figure 5D). These data suggest that the inhi-
bition is due to the engagement of LAR phosphatases rather
than a co-engagement of inhibitory Fc receptors, similar to
anti-BDCA2 antibodies (Pellerin et al., 2015).
Consistent with prior reports (Balmelli et al., 2011; Fujita et al.,
2013; Wang et al., 2014), CpG-induced YFP expression by
HoxB8-IfnbYFP cells was reduced by an inhibitor of tyrosine
phosphorylation (Figure 5E). The inhibitory effect of anti-PTPRS
wasminimal in the presence of the inhibitor, suggesting that LAR
phosphatases exert their function by reducing tyrosine phos-
phorylation in pDCs. Indeed, PTPRS crosslinking abolished
CpG-induced tyrosine phosphorylation in HoxB8-IfnbYFP and
Gen2.2 cells as determined by flow cytometry (data not shown).
Heparan sulfate (HS)-containing proteoglycans (HSPG) repre-
sent a major class of PTPRS ligands that cross-link PTPRS via
their HS moieties; conversely, chondroitin sulfate proteoglycans
(CSPG) might antagonize PTPRS by preventing its crosslinking
by HS (Coles et al., 2011). We found that the prototypical
HSPG ligand of PTPRS, glypican, inhibited Ifnb expression by
HoxB8-IfnbYFP cells (Figures 5F and 5G), whereas CSPG neuro-
can enhanced it (Figure 5F). The inhibitory effect of glypican and(Ctrl) animals and stained for anti-PTPRS and surface markers. Shown are
profiles of GFP fluorescence and PTPRS staining in the indicated gated
populations.
(E) The expression of LAR phosphatases in murine pDCs after activation. Total
BM cells were incubated with medium only or CpG for 16 hr, stained for cell
surface markers, fixed, and stained for intracellular IFN-a. Shown are staining
intensities of the indicated proteins in gated pDCs.
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B Figure 5. Ptprs and Ptprf Inhibit the Activa-
tion of Murine pDCs
Murine HoxB8-FL cell line carrying the YFP knock-
in reporter alleles of Ifnb (HoxB8-IfnbYFP) was
differentiated into pDCs, activated with CpG in
the indicated conditions, and analyzed for YFP
expression.
(A) Surface phenotype of the differentiated HoxB8-
IfnbYFP cell clone used for the analysis.
(B) The expression of IfnbYFP reporter and LAR
phosphatases in HoxB8-IfnbYFP cells activated
with CpG for the indicated time periods.
(C) The effect of LAR phosphatases crosslinking
on Ifnb induction in HoxB8-IfnbYFP cells. Shown
are the fractions of YFP+ cells within HoxB8-Ifn-
bYFP cells activated with CpG for 3–5 hr in the
plates pre-coated with control IgG or anti-PTPRS
(each symbol represents an independent experi-
ment).
(D) The effect of Fc receptor blockade on the
inhibitory activity of anti-PTPRS. Shown are YFP
expression profiles of HoxB8-IfnbYFP cells acti-
vated with CpG on plate-bound control IgG or anti-
PTPRS without any additional treatments (none),
or in the presence of blocking anti-FcR antibody
(Fc Block) or normal goat serum. Alternatively,
control IgG or anti-PTPRS were bound to the plate
via Fc fragments by pre-coating with anti-goat IgG
(Fc) secondary antibodies (anti-Fc bound).
(E) The role of tyrosine phosphorylation in the Ifnb
expression by HoxB8-IfnbYFP cells. Cells were
activated with CpG on plates pre-coated with control IgG or anti-PTPRS, with or without the tyrosine phosphorylation inhibitor.
(F) The effect of known LAR phosphatase ligands on Ifnb expression by HoxB8-IfnbYFP cells. Cells were activated with CpG on plates pre-coated with re-
combinant glypican or neurocan.
(G) The effect of glypican on Ifnb expression within HoxB8-IfnbYFP cells activated with CpG for 3–5 hr (each symbol represents an independent experiment).of HS on IFN expression was observed both in HoxB8-IfnbYFP
cells and in primary BM pDCs (Figure S4). While glypican and
other HSPGmight engagemultiple receptors on pDCs, the inhib-
itory effects of this known PTPRS ligand are consistent with the
proposed inhibitory role of LAR phosphatases.
Ptprs and Ptprf Restrict the Activation of Murine pDCs
We tested the role of Ptprs and Ptprf in the development and
function of pDC lineage. Because Ptprs-deficient animals on
B6 background die perinatally, we used fetal liver cells from dou-
ble-deficient Ptprs/ Ptprf/ embryos to reconstitute irradi-
ated recipients. The fraction of peripheral pDCs among the
donor-derived cells in the resulting LAR double-knockout
(LAR-KO) chimeras was slightly increased (Figure S5A). To
analyze animals in the steady state without irradiation, we exam-
ined the viable Ptprs+/ Ptprf/ mice, which show a profound
reduction of Ptprs and Ptprf surface expression (Figure 4C).
The pDC fraction in these ‘‘LAR three-quarter knockout’’
(LAR3/4 ) mice was normal in the BM and spleen but slightly
increased in the lymph nodes (Figure S5B). The expression of
lineage and activation markers in pDCs from both LAR-KO
chimeras and LAR3/4 mice was normal, suggesting that LAR
phosphatases are generally dispensable for the development
and homeostasis of murine pDCs.
Despite the normal number of pDCs, the CpG-induced secre-
tion of IFN-a was higher in LAR-KO BM, suggesting a higher ac-
tivity per pDC (Figure 6A). Indeed, sorted LAR3/4 pDCs showed282 Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc.higher induction of Ifna at 24 hr after activation (Figure 6B).
Furthermore, LAR3/4 pDCs showed an earlier and stronger in-
duction of Ifnb and of several IFN-inducible genes at 18–24 hr af-
ter activation (Figure 6C). Global CpG-induced IFN production
in vivo was comparable among control and LAR3/4 mice, likely
due to the strong overriding effect of CpG injection (data not
shown). However, naive LAR3/4 mice showed a significantly
increased baseline amounts of serum IFN-a and IFN-b (Fig-
ure 6D). Thus, reduced dosage of LAR phosphatases is associ-
ated with enhanced IFN expression by pDCs and spontaneous
systemic IFN production in the steady state.
The Loss of LAR Phosphatases in Hematopoietic Cells
Causes Colitis
Given the persistent microbial exposure in the gut and the asso-
ciation of PTPRSwith colitis, we examined the intestinal immune
system of LAR-deficient mice. The fraction of CD45+ hema-
topoietic cells was significantly increased in the intestinal epithe-
lial preparations of LAR3/4 mice, revealing immune cell infiltration
(Figure 6E). The relative proportions of various immune cell
types in the intestinal epithelium and LP were not significantly
changed, although LP lymphocytes showed a trend toward
increased IFN and IFN-inducible gene expression (Figure S5C).
Importantly, samples of colon tissue showed elevated expres-
sion of Ifna transcript (Figure 6F), suggesting that the observed
infiltration is accompanied by net increase in local IFN-a
production.
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Figure 6. The Reduction of LAR Phosphatases Leads to pDC Hyperactivation and Colitis
(A) CpG-induced IFN-A production in the BM of mice reconstituted with control or Ptprs/Ptprf/ (LAR-KO) hematopoietic cells. Total BM cells from individual
control and LAR-KO chimeras were incubated with CpG for 24 hr, and IFN-a concentration in the supernatant was measured by ELISA.
(B and C) The expression of IFN and IFN-inducible genes by pDCs from Ptprs+/Ptprf/ (LAR3/4 ) mice. pDCs were sorted from the BM of control and LAR
3/4
mice, stimulated with CpG and examined by qRT-PCR (presented as mean ± SD of triplicate reactions). (B) shows the expression of Ifna after 24 hr after
stimulation (representative of three independent experiments). (C) shows the expression of Ifnb and IFN-inducible genes by the same pDCs at the indicated time
points after stimulation.
(D) Concentrations of IFN-a and IFN-b in the sera of naive LAR3/4 mice as measured by ELISA.
(E) The fraction of CD45+ hematopoietic cells in the small intestinal intraepithelial lymphocyte preparations from individual control and LAR3/4 mice. Each
experiment involved one control and one LAR3/4 animal; because of large variation between experiments, the results are presented as paired analysis.
(F) The expression of IFN-a in the intestinal tissue of LAR3/4 mice. Shown is the expression of Ifna in colon samples from individual control and LAR
3/4 mice as
determined by qRT-PCR relative to a randomly chosen control sample.
(G) Representative sections of the large intestines from LAR3/4 mice and controls. Magnification, 2003; inset illustrates crypt abscess.
(H) The frequency of intestinal inflammation as scored by histopathology, with statistical significance indicated. Numbers of analyzed animals were 13 (LAR3/4
mice), 6 (LAR3/4 controls), 10–11 (LAR-KO chimeras), and 7–9 (control chimeras).
Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc. 283
A B
C
D
Figure 7. The Deletion of LAR Phosphatases
in Dendritic Cells Leads to pDC Hyperactiva-
tion and Colitis
Animals with conditional LAR phosphatase deletion
(LAR-CKO, Ptprf/ Ptprsflox/flox ItgaxCre), or con-
trols (Ptprf+/+ Ptprsflox/flox ItgaxCre-negative in all
panels except C) were examined.
(A) Cytokine production by LAR-CKO pDCs. Total
BM cells were cultured with CpG for 16 hr and
stained for cell surface markers and intracellular
cytokines. Shown are the histograms of IFN-a or
TNF-a staining in gated B220+ SiglecH+ pDCs or in
B220 non-pDC myeloid cells. The threshold of
positive staining and the fraction of positive cells are
indicated. Representative of three experiments.
(B) Leukocyte infiltration in the intestinal LP of LAR-
CKO and control mice. The number of total CD45+
leukocytes or CD3+ T cells recovered from the LP
preparations of individual mice are shown.
(C) Leukocyte and T cell infiltration in the intestinal
LP from co-housed pairs of LAR-CKO and littermate
controls (Ptprf+/ Ptprsflox/flox ItgaxCre-negative).
(D) T cell infiltration in the intestine of LAR-CKO and
control mice. Sections of the indicated intestinal
compartments were stained for CD3 (brown) and
counterstained with hematoxylin (blue).Histological analysis of naive adult LAR3/4 mice revealed mild
colitis and cecal inflammation (typhlitis) with increased leukocyte
infiltration in the LP, in the intercryptal spaces and at crypt bases,
mild edema and occasional crypt abscesses (Figures 6G and
6H). No leukocyte infiltration or overt colitis has been observed
in Ptprf/ Ptprs+/+ mice (data not shown), suggesting that the
combined loss of Ptprs and Ptprf is required for thesemanifesta-
tions. Furthermore, chimeras reconstituted with LAR-KO he-
matopoietic cells showed similar histological manifestations of
colitis and typhlitis (Figure 6H). Thus, the loss of LAR phospha-
tases Ptprs and Ptprf is associated with intestinal inflammation
that is hematopoietic in origin.
Ptprs Expression in Dendritic Cells Restricts pDC
Activation and Colitis
To further elucidate the cell type specificity of LAR phosphatase
function, we generated a mouse strain for Cre recombinase-
mediated conditional targeting of Ptprs (Ptprsflox). Because284 Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc.pDC-specific Cre deleter strains are not
available, we used the ItgaxCre strain that
deletes genes in all CD11c+ DC subsets
including pDCs and cDCs. The resulting
mice with DC-specific deletion of Ptprs
(Ptprsflox/flox ItgaxCre) were viable, had no
abnormalities in the DC lineage composi-
tion or function, and showed no signs of
colitis (data not shown). We therefore
crossed these mice onto Ptprf null back-
ground to generate Ptprf/ Ptprsflox/flox
ItgaxCre mice that lack both LAR phospha-
tases in the DC lineage (DC-specific LAR
conditional knockout, LAR-CKO). LAR
phosphatase expression on pDCs fromLAR-CKO mice was reduced in the BM and nearly abolished in
the spleen (Figure S6A). Consistent with the weak expression
of Ptprs in human and murine cDCs (Figures S1A, 4A, and
S3A), cDCs showed weak staining that was reduced by the
loss of Ptprs, but not Ptprf. These data confirm that the co-
expression of the two LAR phosphatases is specific to pDCs
and has been ablated in LAR-CKO mice, albeit with delayed
kinetics.
The number and phenotype of pDCs were not significantly
changed in LAR-CKO mice, although a trend toward higher
pDC fraction in the LN was noted (data not shown). Upon stimu-
lation of total BM with CpG, pDCs from LAR-CKO mice showed
higher frequency of IFN-a and TNF-a-producing cells compared
to controls (Figure 7A). Consistent with the pDC-specific
effect, the fraction of TNF-a-producing cells among non-pDCs
was not increased. Intestinal LP cell preparations of LAR-CKO
mice showed significantly increased numbers of CD45+ cells
and CD3+ T cells (Figure 7B). The same increase was evident
in co-housed pairs of LAR-CKO mice and control littermates
(Figure 7C). All cell types including B and T cells were increased
in numbers, but not in relative proportions (Figure S6B); similarly,
no change in the proportion of LP T cells producing IL-17 and/or
IFN-g was detected (Figure S6C). The infiltration of T cells
was confirmed by immunochemical staining of large and
small intestine (Figure 7D). Finally, LAR-CKO mice exhibited his-
tological colitis that was weaker than in LAR3/4 mice but signifi-
cant compared to controls (Figure S6D). Thus, DC-specific
loss of Ptprs on Ptprf null background is associated with hy-
per-responsiveness of pDCs and mild intestinal inflammation,
partially recapitulating the phenotype of global Ptprs/Ptprf
reduction. Because the expression of Ptprs and Ptprf within
the DC lineage is restricted to pDCs, these results suggest that
LAR phosphatases inhibit pDC activation and consequently pro-
mote immune homeostasis in the intestine.
DISCUSSION
LAR-type receptor tyrosine phosphatases PTPRS and PTPRF
regulate the development and function of multiple tissues
including genitourinary tract, mammary gland, and brain. Here
we show that PTPRS is also expressed in the immune system,
where it appears specific for the pDC lineage in both humans
and mice. This conserved pDC-specific expression is controlled
by E2-2, a similarly conserved transcriptional regulator of pDC
development and maintenance. In addition, we found that Ptprf
is expressed in murine, but not in human pDCs. The expression
of PTPRS was prominent on the surface of naive pDCs but was
rapidly reduced upon activation, likely through internalization
and/or shedding from the membrane. Notably, IFN-a-producing
cells were contained in the pDC population with the lowest sur-
face expression of PTPRS, suggesting that a threshold of PTPRS
reduction might be necessary for cytokine production by acti-
vated pDCs.
Consistent with the inverse relationship between PTPRS ex-
pression and IFN production, antibody-mediated crosslinking
of PTPRS inhibited pDC activation in primary human pDCs, a hu-
man pDC cell line and in vitro-derived murine pDCs. Conversely,
inducible knockdown of PTPRS and genetic reduction of Ptprs/
Ptprf in primary murine pDCs enhanced TLR-induced pDC acti-
vation. These combined data from diverse experimental systems
in two species suggest that PTPRS (along with Ptprf in the
mouse) is a pDC-specific inhibitory receptor. Indeed, antibodies
to known inhibitory receptors including BDCA-2, ILT7, and Si-
glecH reduce IFN production by pDCs (Blasius et al., 2004;
Cao et al., 2006; Dzionek et al., 2001). Furthermore, BDCA-2
and ILT7 are downregulated following TLR-induced pDC activa-
tion in vitro (Meyer-Wentrup et al., 2008; Tavano et al., 2013). Un-
like all these receptors, however, the expression and function of
PTPRS in pDCs appear similar in mice and humans. The identi-
fication of a conserved pDC-specific inhibitory receptor strongly
supports the genetic and functional conservation of the pDC
lineage in mammals. It also highlights the evolutionary pressure
for lineage-specific regulatory mechanisms that restrict the
powerful cytokine-producing capacity of pDCs.
The crosslinking of PTPRS inhibited both the IRF7-depen-
dent pathway of IFN production and the NF-kB-dependent
inflammatory pathway, suggesting that PTPRS might blockan upstream tyrosine phosphorylation-dependent mechanism
of pDC activation. Tyrosine phosphorylation is required for
optimal IFN production by pDCs and involves both the Src fam-
ily kinase pathway and yet unidentified Src-independent com-
ponents (Balmelli et al., 2011; Fujita et al., 2013; Wang et al.,
2014). Interestingly, the Src pathway also mediates the inhibi-
tory signaling through ITAM-dependent pDC-specific receptors
(Gilliet et al., 2008). Thus, PTPRS might restrict tyrosine phos-
phorylation-dependent pathways downstream of TLR signaling
in quiescent pDCs, whereas its rapid loss upon pDC activation
might enable subsequent signaling by other inhibitory recep-
tors. Whereas the physiological ligands of PTPRS in pDCs
remain to be defined, they are likely to be broadly available in
tissues to ensure constitutive signaling in the steady state. In
that respect, known PTPRS ligands HSPG are major compo-
nents of the extracellular matrix and cell membranes, and we
here observed their inhibitory effect on pDC activation. Indeed,
HSPG were recently proposed to inhibit IFN production by
macrophages in the context of atherosclerosis (Gordts et al.,
2014). The HSPG that are most relevant for pDC function
remain to be identified, and they might signal through PTPRS
as well as other surface receptors on pDCs. Of note, BDCA-2
and SiglecH are lectins that appear to bind specific carbohy-
drate modifications, e.g., asialo-galactosyl oligosaccharides in
the case of BDCA-2 (Riboldi et al., 2011). Therefore, carbohy-
drate components of proteoglycans emerge as major regula-
tors of pDC activity that restrict pDC activation through both
conserved (PTPRS) and species-specific (BDCA-2, SiglecH)
receptors.
The biological role of pDC-specific inhibitory receptors is still
poorly understood. Deletion of SiglecH, the only murine receptor
known so far, did not cause overt autoimmune or inflammatory
diseases. SiglecH-deficient mice show higher IFN response to
murine cytomegalovirus (MCMV), whereas other immune pheno-
types in these mice are not pDC-intrinsic (Puttur et al., 2013;
Swiecki et al., 2014). We found that Ptprs reduction or DC-spe-
cific deletion on Ptprf null background caused mild spontaneous
colitis that could be transferred with hematopoietic cells.
Although the colitis in Ptprs-deficient mice (Muise et al., 2007)
or in compound Ptprs/Ptprf mice (this study) might have com-
plex origins and involve the function of LAR phosphatases in
other cell types, the pDC-intrinsic function of Ptprs appears
essential. Notably, pDC hyperactivation has been documented
in inflammatory bowel disease (Baumgart et al., 2011) and in co-
litis associated with the Wiskott-Aldrich syndrome (Prete et al.,
2013). Consistent with the emerging key role of DCs as regula-
tors of intestinal inflammation (Bar-On et al., 2011; Bogunovic
et al., 2012), our results suggest that a primary pDC hyperactiva-
tion might be linked to disrupted immune homeostasis in the
intestine.
In conclusion, we describe the LAR phosphatase PTPRS as an
evolutionarily conserved pDC-specific receptor that restricts
pDC activation and thereby maintains immune homeostasis.
Due to their important role in autoimmune diseases such as
lupus (Rowland et al., 2014; Sisirak et al., 2014), pDCs have
emerged as a target of immunotherapies such as antibody-
mediated depletion. Given the expression of PTPRS in non-im-
mune tissues such as the brain, other pDC-specific receptors
such as BDCA-2 might provide better targets for depletingImmunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc. 285
antibodies (Pellerin et al., 2015). On the other hand, the conser-
vation and potent activity of PTPRS make it an attractive candi-
date for the modulation of pDC function, e.g., via cross-linking
with non-depleting agonist antibodies. Conversely, recently
developed peptides that selectively inhibit PTPRS (Lang et al.,
2015) might be utilized to boost the insufficient activity of pDCs
in conditions like chronic viral infections or tumors.
EXPERIMENTAL PROCEDURES
Primary Human Cells
All human studies were performed according to the investigator’s protocol
approved by the Institutional Review Board of Columbia University. PBMC
were isolated from healthy adult volunteers by Histopaque density gradient
centrifugation; where indicated, pDCs were enriched using the Diamond
pDC isolation kit (Miltenyi Biotec) to >95% purity. Human PBMC subsets for
expression analysis were purchased from Allcells.
For pDC activation, PBMCs were plated at 5 3 105 /well of flat-bottom 96
well plates in RPMI medium with 10% FCS in the presence of affinity-purified
polyclonal goat IgG antibody to the extracellular domain of human PTPRS
(R&D Systems) or of control goat IgG (Santa Cruz Biotechnology). In titration
experiments, antibody concentrations >0.01 mg/mL were found to have the
same effect. CpG type A (ODN 2216, Invivogen) was added 1 hr later at
5 mM concentration. After 6 hr, protein transport inhibitor (BD Golgi Plug,
BD Biosciences) was added and cells were incubated for additional 10 hr.
For the analysis by immunofluorescence, purified pDC were pre-incubated
with anti-PTPRS or control IgG and then activated with CpG for 3 hr.
Animals
All mouse studies were performed according to the investigator’s protocol
approved by the Institutional Animal Care and Use Committee of Columbia
University. The Ptprf and Ptprf mutant strains and crosses thereof are
described in the Supplemental Experimental Procedures.
Cell Lines
The culture and analysis of human pDC cell lines CAL-1 and Gen2.2 and of the
mouse HoxB8-transformed cell line with pDC differentiation potential and IFN-
b reporter (HoxB8-IfnbYFP) are described in the Supplemental Experimental
Procedures.
Cell and Gene-Expression Analysis
To detect PTPRS expression on human PBMC and pDC cell lines, we
incubated cells with 10% normal mouse serum, washed, and stained with
0.5 mg/ml goat anti-PTPRS (R&D Systems) followed by a secondary PE-conju-
gated F(ab’)2 fragment of donkey anti-goat IgG pre-adsorbed against other
species (Jackson ImmunoResearch). For staining mouse cells, the blocking
step was omitted. Cells were then stained with directly conjugatedmonoclonal
antibodies against cell surface markers. Cells were acquired using BD LSRII or
BD Fortessa (BD Biosciences), and data were analyzed using FlowJo software
(Treestar). The detection of intracellular cytokines, immunofluorescence mi-
croscopy, and the isolation and analysis of intestinal leukocytes were done
as described in the Supplemental Experimental Procedures.
ChIP-seq analysis and shRNA-mediated knockdown of human TCF4 (E2-2)
in pDC cell lines has been described (Ghosh et al., 2014; Sawai et al., 2013).
For qRT-PCR analysis, stained cell suspensions were sorted directly into Trizol
LS reagent (Invitrogen) using FACSAria II cell sorter (BD Biosciences). The iso-
lated total RNA was reverse transcribed and assayed by SYBR green-based
real-time PCR with MX3000P instrument (Stratagene). The expression of all
genes was normalized to that of Actb or (for intestinal tissue) of Hprt, and ex-
pressed relative to the indicated reference sample via the DDCT method. Mu-
rine IFN-a and IFN-b were measured in culture supernatants and in sera using
sandwich ELISA with primary antibody pairs from PBL Interferon Source.
Statistical Analysis
Statistical significance was estimated using two-tailed Student’s t test; un-
paired and paired t tests, respectively, were used for pooled groups or
matched pairs as indicated. Immunofluorescence parameters were analyzed286 Immunity 43, 277–288, August 18, 2015 ª2015 Elsevier Inc.using the chi-square test. Histological scores were analyzed using Wilcoxon
signed-rank test.
SUPPLEMENTAL INFORMATION
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